论文部分内容阅读
目的 研究膀胱癌组织中p16、c -erbB - 2和 p5 3蛋白表达 ,探讨其与膀胱癌病理分级、临床分期和转移的关系。方法 应用免疫组化SP法对 75例膀胱癌组织中p16、p5 3及c-erbB - 2蛋白表达进行检测。结果 75例膀胱癌中p16、p5 3及c-erbB - 2的阳性率分别为 41.3%(31/75 )、44 %(33/75 )和 40 %(30 /75 ) ,p16和c -erbB - 2基因在膀胱癌中的阳性率与肿瘤病理分级和临床分期有显著性统计学意义 (P <0 .0 5 ) ,p5 3和c -erbB - 2阳性率与肿瘤临床分期及转移有密切的关系 (P <0 .0 1)。77.3%(5 8/75 )肿瘤有上述癌基因和 (或 )抑癌基因的异常表达 ,其中 5 3.3%(40 /75 )的肿瘤同时有多个基因的表达异常。结论 肿瘤的多基因分析比单基因分析更有价值 ,癌基因c -erbB - 2和抑癌基因p5 3、p16基因的表达异常及协同作用在膀胱癌的发生发展中起重要作用。
Objective To study the expression of p16, c-erbB-2 and p5 3 protein in bladder cancer, and to explore its relationship with pathological grade, clinical stage and metastasis of bladder cancer. Methods The expressions of p16, p5 3 and c - erbB - 2 protein in 75 cases of bladder cancer were detected by immunohistochemical SP method. Results The positive rates of p16, p5 3 and c - erbB - 2 in 75 cases of bladder cancer were 41.3% (31/75), 44% (33/75) and 40% (30/75), respectively. The positive rates of p16 and c - erbB The positive rates of p - 3 and c - erbB - 2 in bladder cancer were significantly correlated with the tumor pathological grade and clinical stage (P <0.05). The positive rates of p5 3 and c - erbB - 2 were significantly correlated with the clinical stage and metastasis (P <0. 01). 77.3% (58/75) of the tumors had aberrant expression of the above oncogenes and / or tumor suppressor genes, of which 3.3% (40/75) of the tumors had abnormal expression of multiple genes at the same time. Conclusions Multi - gene analysis of tumors is more valuable than single - gene analysis. Abnormal expression of c - erbB - 2 and p53, p16 gene and their synergistic effects play an important role in the development of bladder cancer.